PHARMACOKINETIC AND TOXICOLOGICAL EVALUATION OF NOVEL BIOACTIVE COMPOUNDS USING IN SILICO ADMET PREDICTION

Authors

  • Dr. Nathaniel J. Brooks Department of Pharmaceutical Chemistry, Global Center for Biomedical Research, USA

Keywords:

ADMET; pharmacokinetics; toxicity; in silico prediction; SwissADME; pkCSM; hERG; cytochrome P450; drug-induced liver injury; lead optimization.

Abstract

Early pharmacokinetic and toxicological profiling is a central component of contemporary drug discovery because potent molecules may fail when exposure, metabolism, distribution, or safety properties are unfavorable. The present study describes an integrated in silico ADMET framework for prioritizing novel bioactive compounds before resource-intensive experimental testing. The workflow combines physicochemical and drug-likeness descriptors with predicted intestinal absorption, aqueous solubility, plasma protein binding, cytochrome P450 interactions, systemic clearance, hERG-related cardiotoxicity, Ames mutagenicity, and drug-induced liver injury liability. A structured literature-based methodology was established around widely used platforms and model classes including SwissADME, pkCSM, admetSAR, ADMETlab, ProTox-II, and contemporary deep-learning approaches. To demonstrate interpretation, an illustrative eight-compound dataset was evaluated with a consensus desirability score; these numerical outputs are methodological examples rather than experimentally measured or independently validated predictions. The integrated analysis shows how apparently favorable oral absorption can coexist with metabolic inhibition or toxicity liabilities, emphasizing the need for multi-endpoint rather than single-parameter optimization. Compounds with balanced lipophilicity, moderate polar surface area, acceptable solubility, lower CYP inhibition probability, and reduced hERG, mutagenicity, and hepatotoxicity signals were prioritized. In silico ADMET prediction can substantially improve early triage, but applicability domains, data quality, endpoint imbalance, model uncertainty, and inter-platform discordance must be considered. The proposed framework is suitable for hypothesis generation and lead prioritization and should be followed by orthogonal in vitro ADME and toxicology assays before translational decisions.

References

1. Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001). Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Advanced Drug Delivery Reviews, 46(1-3), 3-26. https://doi.org/10.1016/S0169-409X(00)00129-0

2. Egan, W. J., Merz, K. M., Jr., & Baldwin, J. J. (2000). Prediction of drug absorption using multivariate statistics. Journal of Medicinal Chemistry, 43(21), 3867-3877. https://doi.org/10.1021/jm000292e

3. Veber, D. F., Johnson, S. R., Cheng, H. Y., Smith, B. R., Ward, K. W., & Kopple, K. D. (2002). Molecular properties that influence the oral bioavailability of drug candidates. Journal of Medicinal Chemistry, 45(12), 2615-2623. https://doi.org/10.1021/jm020017n

4. Delaney, J. S. (2004). ESOL: Estimating aqueous solubility directly from molecular structure. Journal of Chemical Information and Computer Sciences, 44(3), 1000-1005. https://doi.org/10.1021/ci034243x

5. Pires, D. E. V., Blundell, T. L., & Ascher, D. B. (2015). pkCSM: Predicting small-molecule pharmacokinetic and toxicity properties using graph-based signatures. Journal of Medicinal Chemistry, 58(9), 4066-4072. https://doi.org/10.1021/acs.jmedchem.5b00104

6. Daina, A., Michielin, O., & Zoete, V. (2017). SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Scientific Reports, 7, 42717. https://doi.org/10.1038/srep42717

7. Banerjee, P., Eckert, A. O., Schrey, A. K., & Preissner, R. (2018). ProTox-II: A webserver for the prediction of toxicity of chemicals. Nucleic Acids Research, 46(W1), W257-W263. https://doi.org/10.1093/nar/gky318

8. Li, Y., Cheng, L., Liu, Z., Chen, X., Tang, Y., & Li, W. (2019). admetSAR 2.0: Web-service for prediction and optimization of chemical ADMET properties. Bioinformatics, 35(6), 1067-1069. https://doi.org/10.1093/bioinformatics/bty707

9. Xiong, G., Wu, Z., Yi, J., Fu, L., Yang, Z., Hsieh, C., Yin, M., Zeng, X., Wu, C., Lu, A., Chen, X., Hou, T., & Cao, D. (2021). ADMETlab 2.0: An integrated online platform for accurate and comprehensive predictions of ADMET properties. Nucleic Acids Research, 49(W1), W5-W14. https://doi.org/10.1093/nar/gkab255

10. Myung, Y., de Sá, A. G. C., et al. (2024). Deep-PK: Deep learning for small molecule pharmacokinetic and toxicity prediction. Nucleic Acids Research, 52(W1), W469-W475. https://doi.org/10.1093/nar/gkae254

11. Wu, Z., Ramsundar, B., Feinberg, E. N., Gomes, J., Geniesse, C., Pappu, A. S., Leswing, K., & Pande, V. (2018). MoleculeNet: A benchmark for molecular machine learning. Chemical Science, 9(2), 513-530. https://doi.org/10.1039/C7SC02664A

12. Shan, M., Jiang, C., & Qin, L. P. (2022). A review of computational methods in predicting hERG channel blockers. ChemistrySelect, 7(31), e202201221. https://doi.org/10.1002/slct.202201221

13. Chu, C. S. M., Simpson, J. D., O'Neill, P. M., & Berry, N. G. (2021). Machine learning - Predicting Ames mutagenicity of small molecules. Journal of Molecular Graphics and Modelling, 109, 108011. https://doi.org/10.1016/j.jmgm.2021.108011

14. Zhai, J., Man, V. H., Ji, B., Cai, L., & Wang, J. (2023). Comparison and summary of in silico prediction tools for CYP450-mediated drug metabolism. Drug Discovery Today, 28(10), 103728. https://doi.org/10.1016/j.drudis.2023.103728

15. Bassan, A., Alves, V. M., Amberg, A., et al. (2021). In silico approaches in organ toxicity hazard assessment: Current status and future needs in predicting liver toxicity. Computational Toxicology, 20, 100187. https://doi.org/10.1016/j.comtox.2021.100187

Published

2026-09-20